TRACON Pharmaceuticals (TCON) Insider Trading & Ownership $0.05 +0.02 (+66.67%) (As of 10:27 AM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends TRACON Pharmaceuticals (NASDAQ:TCON) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.27%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$2.93 MNumber OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$2,188.80 Get TCON Insider Trade Alerts Want to know when executives and insiders are buying or selling TRACON Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TCON Insider Buying and Selling by Quarter Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide TRACON Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/26/2023Charles TheuerCEOBuy199$13.20$2,626.80 3/9/2023Opaleye Management Inc.Major ShareholderBuy8,725$27.60$240,810.00 2/28/2023Charles TheuerCEOBuy10$30.40$304.00 1/18/2023Charles TheuerCEOBuy340$32.40$11,016.00 12/14/2022Charles TheuerCEOBuy1,150$25.80$29,670.00 12/14/2022Opaleye Management Inc.Major ShareholderBuy8,375$25.00$209,375.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/6/2022Opaleye Management Inc.Major ShareholderSell76$28.80$2,188.80 11/18/2022Charles TheuerCEOBuy695$28.20$19,599.00 11/2/2022Charles TheuerCEOBuy300$31.80$9,540.00 10/18/2022Opaleye Management Inc.Major ShareholderBuy625$33.00$20,625.00 10/7/2022Charles TheuerCEOBuy250$35.40$8,850.00 10/3/2022Charles TheuerCEOBuy250$33.40$8,350.00 9/29/2022Opaleye Management Inc.Major ShareholderBuy470$34.80$16,356.00 9/27/2022Opaleye Management Inc.Major ShareholderBuy85$33.80$2,873.00 9/22/2022Charles TheuerCEOBuy250$35.20$8,800.00 9/22/2022Opaleye Management Inc.Major ShareholderBuy865$34.60$29,929.00 9/19/2022Opaleye Management Inc.Major ShareholderBuy250$37.40$9,350.00 9/12/2022Scott B BrownCFOBuy125$40.40$5,050.00 7/26/2022Opaleye Management Inc.Major ShareholderBuy112$34.40$3,852.80 7/22/2022Charles TheuerCEOBuy225$37.00$8,325.00 7/14/2022Opaleye Management Inc.Major ShareholderBuy359$36.20$12,995.80 7/12/2022Charles TheuerCEOBuy150$37.40$5,610.00 6/24/2022Opaleye Management Inc.Major ShareholderBuy570$27.80$15,846.00 6/21/2022Opaleye Management Inc.Major ShareholderBuy42,099$26.20$1,102,993.80 5/10/2022Opaleye Management Inc.Major ShareholderBuy485$35.20$17,072.00 5/9/2022Charles TheuerCEOBuy500$37.00$18,500.00 5/6/2022Charles TheuerCEOBuy125$39.40$4,925.00 4/29/2022Charles TheuerCEOBuy250$39.40$9,850.00 4/25/2022Opaleye Management Inc.Major ShareholderBuy538$43.60$23,456.80 4/22/2022Opaleye Management Inc.Major ShareholderBuy2,100$44.80$94,080.00 4/21/2022Charles TheuerCEOBuy225$46.00$10,350.00 4/13/2022Opaleye Management Inc.Major ShareholderBuy367$50.00$18,350.00 4/11/2022Opaleye Management Inc.Major ShareholderBuy455$48.40$22,022.00 4/8/2022Charles TheuerCEOBuy100$50.00$5,000.00 3/30/2022Charles TheuerCEOBuy200$54.00$10,800.00 3/29/2022Scott B BrownCFOBuy50$56.40$2,820.00 3/21/2022Charles TheuerCEOBuy60$49.00$2,940.00 1/28/2022Opaleye Management Inc.Major ShareholderBuy25$44.00$1,100.00 1/24/2022Opaleye Management Inc.Major ShareholderBuy868$41.00$35,588.00 1/21/2022Opaleye Management Inc.Major ShareholderBuy1,750$43.80$76,650.00 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!]1/19/2022Opaleye Management Inc.Major ShareholderBuy1,184$44.80$53,043.20 12/29/2021Opaleye Management Inc.Major ShareholderBuy2,616$50.20$131,323.20 12/27/2021Opaleye Management Inc.Major ShareholderBuy4,366$58.40$254,974.40 12/15/2021Opaleye Management Inc.Major ShareholderBuy1,098$48.60$53,362.80 12/13/2021Opaleye Management Inc.Major ShareholderBuy760$52.80$40,128.00 12/6/2021Opaleye Management Inc.Major ShareholderBuy1,136$45.20$51,347.20 12/3/2021Opaleye Management Inc.Major ShareholderBuy4,463$46.00$205,298.00 (Data available from 1/1/2013 forward) TCON Insider Trading Activity - Frequently Asked Questions Who is on TRACON Pharmaceuticals's Insider Roster? The list of insiders at TRACON Pharmaceuticals includes Charles Theuer, Opaleye Management Inc., and Scott B Brown. Learn more on insiders at TCON. What percentage of TRACON Pharmaceuticals stock is owned by insiders? 5.27% of TRACON Pharmaceuticals stock is owned by insiders. Learn more on TCON's insider holdings. Which TRACON Pharmaceuticals insiders have been buying company stock? The following insiders have purchased TCON shares in the last 24 months: Charles Theuer ($43,616.80), and Opaleye Management Inc. ($450,185.00). How much insider buying is happening at TRACON Pharmaceuticals? Insiders have purchased a total of 18,799 TCON shares in the last 24 months for a total of $493,801.80 bought. Which TRACON Pharmaceuticals insiders have been selling company stock? The following insider sold TCON shares in the last 24 months: Opaleye Management Inc. ($2,188.80). How much insider selling is happening at TRACON Pharmaceuticals? Insiders have sold a total of 76 TRACON Pharmaceuticals shares in the last 24 months for a total of $2,188.80 sold. TRACON Pharmaceuticals Key ExecutivesDr. Charles P. Theuer M.D. (Age 60)Ph.D., Chairman, CEO & President Compensation: $646.6kMr. Scott B. Brown CPA (Age 43)M.S., Chief Financial Officer Compensation: $403.1kDr. James L. Freddo M.D. (Age 69)Chief Medical Officer Mr. Ya HuangExecutive Director of Statistical Programming More Insider Trading Tools from MarketBeat Related Companies Bellerophon Therapeutics Insider Buying NexImmune Insider Buying TC Biopharm Insider Buying Seelos Therapeutics Insider Buying Smart for Life Insider Buying Calithera Biosciences Insider Buying Vaxxinity Insider Buying Ampio Pharmaceuticals Insider Buying Comera Life Sciences Insider Buying Evelo Biosciences Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:TCON) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TRACON Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TCON Stock Alerts